<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508390</url>
  </required_header>
  <id_info>
    <org_study_id>H-29665</org_study_id>
    <nct_id>NCT01508390</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate</brief_title>
  <official_title>Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants will have standard Androgen Deprivation Therapy and undergo&#xD;
      standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity&#xD;
      Modulated Radiation Therapy. The subsequent *boost* radiation therapy to the prostate alone&#xD;
      will be given using the CyberKnife, rather than using the standard Intensity Modulated&#xD;
      Radiation Therapy. This study will also see how CyberKnife affects the quality of the&#xD;
      participant's life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, participants will have standard androgen deprivation therapy and undergo&#xD;
      standard radiation therapy to the prostate and at-risk lymph nodes by intensity-modulated&#xD;
      radiation therapy (IMRT). The subsequent *boost* radiation therapy to the prostate alone will&#xD;
      be given using the CyberKnife, rather than using the standard Intensity Modulated Radiation&#xD;
      Therapy. This study will also see how CyberKnife affects the quality of the participant's&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Document rate of biochemical Disease-Free Survival (bDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To document the rate of biochemical Disease-Free Survival (bDFS), American Society for Radiation Oncology definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of local failure</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of local failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant failure</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of distant failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease-specific survival</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of disease-specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicity following combination androgen deprivation therapy, External Beam Radiation Therapy and CyberKnife radiosurgery as a boost</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Boost</intervention_name>
    <description>21 Gy in 7 Gy per day, 3 fractions, Every other day</description>
    <arm_group_label>Boost</arm_group_label>
    <other_name>stereotactic radiotherapy, cyberknife, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven adenocarcinoma of the prostate&#xD;
&#xD;
               1. Gleason score (2-10)&#xD;
&#xD;
               2. Biopsy within six months of date of registration&#xD;
&#xD;
               3. Patient age &gt;18 years&#xD;
&#xD;
          2. Clinical stage (American Joint Committee on Cancer 7th Edition)&#xD;
&#xD;
             a. T-stage determined by physical exam (Digital Rectal Exam Required)&#xD;
&#xD;
             i. MRI findings (e.g. extracapsular extension) can be used to determine T-staging&#xD;
&#xD;
             b. N-stage determined using abdominopelvic CT scan and/or MRI&#xD;
&#xD;
             c. M-stage determined by physical exam, CT and/or MRI, and bone scan (must be M0,&#xD;
             excepting Lymph nodes)&#xD;
&#xD;
             Please note: a SPECT bone scan including a CT of the abdomen and pelvis or an F18&#xD;
             Fluciclovine PET/CT fulfills protocol criteria for both the abdominopelvic CT and bone&#xD;
             scan.&#xD;
&#xD;
          3. Patients must belong to one of the following risk groups:&#xD;
&#xD;
               -  PSA &gt; 20 and &lt; 150 and/or&#xD;
&#xD;
               -  Gleason 8-10 and/or&#xD;
&#xD;
               -  &gt; clinical T3a and/or&#xD;
&#xD;
               -  Clinical N1&#xD;
&#xD;
             OR&#xD;
&#xD;
               -  PSA 10 - 20 AND&#xD;
&#xD;
               -  Gleason 7 AND&#xD;
&#xD;
               -  Clinical T2b - T2c&#xD;
&#xD;
          4. Patient is receiving, or planning to receive standard androgen deprivation therapy and&#xD;
             initial IMRT to the prostate and positive or at-risk lymph nodes.&#xD;
&#xD;
          5. Prostate volume greater than 20 cc and less than 100 cc&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          7. Patient has agreed to complete questionnaires&#xD;
&#xD;
          8. Signed IRB approved informed consent&#xD;
&#xD;
          9. Patient eligible to have an MRI&#xD;
&#xD;
         10. Must be able to tolerate the confinement of an MRI procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No prior prostate surgery (including TURP) or prostate cancer treatment with the&#xD;
             exception of androgen deprivation therapy&#xD;
&#xD;
          2. No prior radiotherapy to the pelvis&#xD;
&#xD;
          3. No implanted hardware (including metal) or other material that would prohibit&#xD;
             appropriate treatment planning or treatment delivery&#xD;
&#xD;
          4. No metastatic disease, with the exception of lymph node positive disease&#xD;
&#xD;
          5. No chemotherapy for a malignancy in the last 5 years.&#xD;
&#xD;
          6. No history of an invasive malignancy (other than basal or squamous skin cancers) in&#xD;
             the last 5 years.&#xD;
&#xD;
          7. No heart pacemaker, No metallic foreign body (metal sliver) in the eye, No aneurysm&#xD;
             clip in the brain&#xD;
&#xD;
          8. No history of a pelvic or horseshoe kidney&#xD;
&#xD;
          9. No diagnosis of inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariel Hirsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariel Hirsch, MD</last_name>
    <phone>617-638-7070</phone>
    <email>ariel.hirsch@bmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Jose, BS</last_name>
    <phone>617-638-8213</phone>
    <email>annie.jose@bmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Jose, BS</last_name>
      <phone>617-638-8213</phone>
      <email>annie.jose@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Ariel Hirsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

